If you have been reading about half-life and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
== Production == Yeast extracts in general are produced in three steps: fermentation (growing the yeast), disruption (breaking of the cells), and separation (to keep the soluble part). Although the vast majority of yeast extract spreads are made using von Liebig's traditional approach of heat-autolysis using surplus yeast from beer brewing, other methods do exist for producing specialized types. In terms of fermentation, spent beer yeast is commonly contaminated with the bitter compounds from hops, requiring a "debittering" step to wash out most of this undesired flavor. Yeast from other sources are not affected by this issue. Spent brewer's yeast is also quite biodiverse, containing yeasts other than traditional Saccharomyces cerevisiae and sometimes beer spoilage-causing lactic acid bacteria too. For disruption of the cell, some physical and chemical methods may be used in place of the heat-autolysis process. Doing so may allow specific compounds to be extracted or to produce an extract without the hydrolysis of cell contents (as in autolysis) happening. Autolysis can be assisted with added enzymes; for example, additional nuclease would enhance the release of nucleosides from RNA. Separation removes insoluble parts, mainly the yeast's cell wall, from the extract. Cell wall can be separated into two commercially useful parts: the glucans as "yeast β-glucan" and the mannans further processed into mannan-oligosaccharide (MOS). The product is finally concentrated by drying, into a thick paste or a dry powder.
The Singapore government states that the death penalty is only used in the most serious of crimes, sending a strong message to potential offenders. They point out that in 1994 and 1999 the United Nations General Assembly failed to adopt United Nations resolutions calling for a moratorium on the death penalty worldwide, as a majority of countries opposed such a move. Singapore's permanent representative to the United Nations wrote a letter to the Special Rapporteur on extrajudicial, summary or arbitrary executions in 2001 which stated:
=== Conflict wounds === In 2018, the Scar Free Foundation Centre for Conflict Wound Research was established at the Royal Centre for Defence Medicine in Queen Elizabeth Hospital, Birmingham. The centre's studies aim to mitigate the physical and psychological impacts of scarring among servicemen, women, and individuals injured in terrorist attacks. It was established in partnership with the CASEVAC Club, a members organisation similar to the Guinea Pig Club.
=== Further reading === Ball, S. J. The Cold War: An International History, 1947–1991 (1998). British perspective Beschloss, Michael, and Strobe Talbott. At the Highest Levels:The Inside Story of the End of the Cold War (1993) Braithwaite, Rodric et al. "Could the Soviet Union Have Survived? We ask four historians whether the demise of one of the 20th century's superpowers was as inevitable as it now seems." History Today (Oct 2020) 70#10 pp 8–10 [online]. Brooks, Stephen G., and William C. Wohlforth. "Power, globalization, and the end of the Cold War: Reevaluating a landmark case for ideas." International Security 25.3 (2001): 5-53. [online] Engel, Jeffrey A. When the World Seemed New: George H. W. Bush and the End of the Cold War (2017) Gaddis, John Lewis. The United States and the End of the Cold War: Implications, Reconsiderations, Provocations (1992) online Garthoff, Raymond. The Great Transition: American-Soviet Relations and the End of the Cold War (1994) online Goertz, Gary and Jack S. Levy, eds. Causal explanations, necessary conditions, and case studies: World War I and the End of the Cold War (2005), 10 essays from political scientists; online Hogan, Michael, ed. The End of the Cold War. Its Meaning and Implications (1992) articles from Diplomatic History Kalinovsky, Artemy M. "New Histories of the End of the Cold War and the Late Twentieth Century." Contemporary European History 27.1 (2018): 149–161. online Kegley Jr, Charles W. "How did the Cold War die? Principles for an autopsy." Mershon International Studies Review 38.Supplement_1 (1994): 11–41.
Water fit for human consumption is called drinking water or potable water. Water that is not potable may be made potable by filtration or distillation, or by a range of other methods. More than 660 million people do not have access to safe drinking water. Water that is not fit for drinking but is not harmful to humans when used for swimming or bathing is called by various names other than potable or drinking water, and is sometimes called safe water, or "safe for bathing". Chlorine is a skin and mucous membrane irritant that is used to make water safe for bathing or drinking. Its use is highly technical and is usually monitored by government regulations (typically 1 part per million (ppm) for drinking water, and 1–2 ppm of chlorine not yet reacted with impurities for bathing water). Water for bathing may be maintained in satisfactory microbiological condition using chemical disinfectants such as chlorine or ozone or by the use of ultraviolet light. Water reclamation is the process of converting wastewater (most commonly sewage, also called municipal wastewater) into water that can be reused for other purposes. There are 2.3 billion people who reside in nations with water scarcities, which means that each individual receives less than 1,700 cubic metres (60,000 cu ft) of water annually. 380 billion cubic metres (13×10^12 cu ft) of municipal wastewater are produced globally each year.
Sources: en.wikipedia.org
=== Books === In September 2019, Sinclair published Lifespan: Why We Age – and Why We Don't Have To co-written with journalist Matthew LaPlante and translated into 18 languages. This was also released as an audiobook on Audible and read by Sinclair. Sinclair broadly discusses his longevity practices on social media and includes them in his book. They include daily doses of nicotinamide mononucleotide (NMN) and resveratrol, which Sinclair claims are activators of SIRT1.
transfer-messenger RNA (tmRNA) A type of RNA molecule in some bacteria which has dual tRNA-like and mRNA-like properties, allowing it to simultaneously perform a number of different functions during translation.
Bluebottle flies are typically 10–14 mm (3⁄8–9⁄16 in) long, almost twice the size of a housefly. The head and thorax are dull gray, and the back of the head has long yellow-orange setae. The abdomen is bright metallic blue with black markings. Its body and legs are covered with black bristly hairs. It has short, aristate antennae and four tarsi per leg. The eyes are red and the wings are transparent. The legs and antennae are black and pink. The chest is bright purple and has spikes for protection from other flies. To differentiate C. vomitoria from other closely related species such as Calliphora vicina, C. vomitoria can be identified by characteristic "orange cheeks", which are the orange hairs below the eyes. Additionally, C. vomitoria has a dark basicosta (base of the wing) while C. vicina has a yellow basicosta. All these characteristics can be identified through a simple photograph.
Maple syrup urine disease (MSUD) is a rare, inherited metabolic disorder that affects the body's ability to metabolize amino acids due to a deficiency in the activity of the branched-chain alpha-ketoacid dehydrogenase (BCKAD) complex. It particularly affects the metabolism of amino acids leucine, isoleucine, and valine. With MSUD, the body is not able to properly break down these amino acids, therefore leading to the amino acids to build up in urine and become toxic. The condition gets its name from the distinctive sweet odor of affected infants' urine and earwax due to the buildup of these amino acids.
Sources: en.wikipedia.org
=== Tax avoidance === In June 2021, the United States Senate Finance Committee, under Chair Ron Wyden (D-OR), began an investigation to determine if the company took advantage of loopholes in the Tax Cuts and Jobs Act of 2017 to significantly reduce its tax liability. In a letter to AbbVie CEO Richard Gonzalez, Wyden noted the company suffered a 2020 pretax loss in the US of $4.5 billion and an overseas pretax profit of $7.9 billion the same year. The report, released in July 2022, showed that AbbVie was able to dodge U.S. taxes by registering intellectual property in offshore jurisdictions such as Bermuda. As a result, while AbbVie received 75% of its sales of Humira in the United States, it only reported 1% of that income for U.S. tax purposes.
The term "Sudetenland" can already be found in geographical literature as early as 1866. In the 19th century, however, the term referred only to the mountain range from the Zittau Basin to the Moravian Gate. In 1902, the publicist and politician Franz Jesser used the term for the first time as a pars pro toto, applying "Sudetenland" to all areas of Bohemia, Moravia, and Austrian Silesia that were then inhabited by a majority of German speakers. Initially, the reception of this newly coined term was slow. In the 1920s, after the territories had become part of Czechoslovakia, publishers, journals, book series, as well as political, popular science, and regional-cultural publications began to adopt it. It eventually also came into circulation as a designation in historical and ethnographic periodicals and monographs. The popularity of the term continued to rise in the 1930, especially after the founding of the Sudetendeutsche Heimatfront in 1933 and later the Sudeten German Party in 1935. In the wake of growing nationalism, the name "Sudetendeutsche" (Sudeten Germans) emerged by the early 20th century. It originally constituted part of a larger classification of three groupings of Germans within the Austro-Hungarian Empire, which also included "Alpine Deutschen" (Alpine Germans) in what later became the Republic of Austria and "Balkandeutsche" (Balkan Germans) in Hungary and the regions east of it. Of these three terms, only the term "Sudetendeutsche" survived, because of the ethnic and cultural conflicts within Bohemia.
December 7, 1995: Decree concerning the responsibilities of the Minister Delegate for Employment. June 6, 1996: Manifesto for gender parity published in L'Express; ten women, including former prominent ministers, are its authors. July 5, 1996: Law concerning adoption. January 14, 1997: Publication of selected excerpts from lawyer Gisèle Halimi's report to the Prime Minister on gender inequalities (social, economic, political), which undermine aspects of democracy; the report also proposes various solutions to reduce these inequalities and promote better democracy. June 11, 1997: Decree concerning the responsibilities of the Minister of Employment and Solidarity. December 19, 1997: Social Security Financing Law for 1998; it includes provisions relating to the family. March 8, 1998: Circular concerning the feminization of job titles, functions, ranks, or titles. March 16, 1998: Law concerning nationality. May 11, 1998: Law concerning the entry and residence of foreigners in France and the right of asylum. June 17, 1998: Constitutional bill for gender equality, including possibilities for measures promoting gender parity in political positions. June 17, 1998: Law concerning the prevention and repression of sexual offenses and the protection of minors. November 17, 1998: A State Secretariat for Women's Rights and Vocational Training is delegated to the Ministry of Employment and Solidarity. December 23, 1998: Social Security Financing Law for 1999, notably modifying certain elements relating to family allowances and the back-to-school allowance.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Ice formation concentrates solutes and can mechanically stress the peptide or damage the delivery device. Thawing afterwards may leave aggregates that are not visible to the eye. Refrigeration keeps the solution above its freezing point while slowing chemical degradation.